Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

Ahead of print publication  

Expected usefulness of the third dose COVID-19 vaccine for cancerous patient

1 Private Academic Consultant Center, Bangkok, Thailand
2 Deparment of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India

Date of Submission23-Jun-2021
Date of Decision30-Jun-2021
Date of Acceptance03-Jul-2021
Date of Web Publication22-Jun-2022

Correspondence Address:
Rujittika Mungmunpuntipantip,
Private Academic Consultant Center, Bangkok
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.jcrt_1007_21

How to cite this URL:
Mungmunpuntipantip R, Wiwanitkit V. Expected usefulness of the third dose COVID-19 vaccine for cancerous patient. J Can Res Ther [Epub ahead of print] [cited 2022 Aug 18]. Available from: https://www.cancerjournal.net/preprintarticle.asp?id=347979


COVID-19 vaccine is the hope for the management of worldwide COVID-19 outbreak. An important consideration for the new COVID-19 is on its efficacy. At present, most new COVID-19 requires the second dose boostering for promoting of effective immunity. In normal person, a two-dose vaccination can produce up to 100% protective antibody.[1] However, the postvaccination COVID-19 is sporadically reported and it leads to question on the present COVID-19 vaccination practice. There is a new idea for a three-dose vaccination for promoting a more effective immunity.[1]

A three-dose vaccination might be useful for some specific group with problem on postvaccination immunity production. For cancerous patient, a previous report shows that the second dose COVID-19 vaccine can increase immunity, but still less than normal person. Here, the authors estimate the utility of the third dose COVID-19 vaccine for cancerous patient. A clinical mathematical model study is used for calculating expected usefulness of the third dose COVID-19 vaccine for cancerous patient. Primary data from a previous referencing publication[2] are used for modeling. For case with solid cancer, the antisevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin-G (IgG) responses are equal to 38% (range: 26–51) and 95% (range: 75–99) after the first and second (at 33 weeks) COVID-19 dose, respectively.[2] For case with hematological cancer, the anti-SARS-CoV-2 IgG responses are equal to 18% (range: 10–32) and 60% (range: 23–88) after the first and second COVID-19 dose, respectively.[2]

The calculated increasing anti-SARS-CoV-2 IgG responses due to vaccine boostering are equal to 57%/3 weeks and 42%/3 weeks for solid cancer and hematological cancer groups, respectively. This value is used for the estimation of the effect of the additional third dose. If the third COVID-19 vaccine dose is given at the next week period after the second dose, the expected the anti-SARS-CoV-2 IgG responses will be equal to 100% and 100% (range: 65–100) for solid cancer and hematological cancer groups, respectively. From this modeling, it can show that the third dose of COVID-19 vaccine will be very useful for any cancerous patients.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

 > References Top

Iversen PL, Bavari S. Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2? Lancet Infect Dis 2021;21:1054-55.  Back to cited text no. 1
Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study. Lancet Oncol 2021;22:765-78.  Back to cited text no. 2


     Search Pubmed for
    -  Mungmunpuntipantip R
    -  Wiwanitkit V
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded0    

Recommend this journal